Study of ALXN2050 in Participants With Hepatic Impairment
Study Identifier:
ALXN2050-HV-109
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Study Details
Medical Condition
- Unmapped
- Other
Study Drug
- Drug: ALXN2050
Date
Apr 2022 - Aug 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A
Requirements Information
Sex
Female & Male
Age
N/A - N/A
Study Details
Medical Condition
- Unmapped
- Other
Study Drug
- Drug: ALXN2050
Date
Apr 2022 - Aug 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information
Protocol Summary
This study will investigate the impact of impaired hepatic function (IHF) on the plasma pharmacokinetics of ALXN2050 in order to provide dosing recommendations for future indications in individuals with varying degrees of IHF.
Trial Locations
Location
Status
Location
Research Site
Hialeah, Florida, United States, 33014
Status
N/A
Location
Research Site
Orlando, Florida, United States, 32809
Status
N/A